Lincoln Pharma reports over 30 percent rise in net profit in Q3
Ahmedabad: Leading healthcare company Gujarat based Lincoln Pharmaceuticals Ltd has reported a net profit of Rs. 17.60 crore for the Q3 FY22 ended December 2021 as against net profit of Rs. 13.49 crore in the corresponding period last year with a robust growth of 30.50 percent .
According to the quarterly results, the net revenue for the Q3 was reported at Rs. 122.52 crore, higher by 6.18 percent over previous fiscal's same period net revenue of Rs.115.39 crore.
Read also: Lincoln Pharma acquires plant in Mehsana for manufacturing Cephalosporin
The Company reported an EBITDA of Rs. 26.09 crore in Q3FY22, a rise of 25.90% as compared to Rs. 20.72 crore in the corresponding period last year. EPS for Q3FY22 was at Rs. 8.79 per share as compared to Rs. 6.73 in the corresponding period last year.
Commenting on the results and performance, Managing Director, Lincoln Pharmaceuticals Ltd, Mahendra Patel, said, "The Company is progressing well on its long-term growth roadmap and we are pleased with the performance so far. Our international business is complementing well with our domestic business to further cement our position in the industry. Progress on the Mehsana expansion for the launch of Cephalosporin products is going as per schedule. Going forward we are confident to improve our growth numbers on all fronts. Strategic growth initiatives, product and geographical expansion, operational efficiency are likely to maximize value for all stakeholders in the near to medium term."
Read also: Lincoln Pharma Gujarat plant gets Australian regulator nod
The company has a manufacturing facility at Khatraj in Ahmedabad, Gujarat. It has developed 600 plus formulations in 15 therapeutic areas and has a strong product/brand portfolio in anti-infective, respiratory system, gynaecology, cardio and CNS, anti-bacterial, ant-diabetic, anti-malaria among others.
Read also: Lincoln Pharma net profit up 28.7pc at Rs. 9.23 Crore in Q4FY20
